GLP-1
Tirzepatide
GLP-1
Tirzepatide 2026 Complete Guide: Dosing, Benefits, Side Effects & Comparison to Semaglutide
Tirzepatide (Zepbound/Mounjaro) delivered 47% greater weight loss than semaglutide in the SURMOUNT-5 trial. Here's the complete 2026 guide to dosing, benefits, side effects, and what compounding restrictions mean for patients.
GLP-1
Tirzepatide 2026: The Complete Guide to Dosing, Weight Loss, and How It Compares to Semaglutide
The landmark SURMOUNT-5 trial proved tirzepatide produces 47% more weight loss than semaglutide. Here's everything you need to know about dosing, side effects, cardiovascular outcomes, and the 2026 legal status of compounded tirzepatide.
GLP-1
Tirzepatide (Mounjaro & Zepbound): The Complete 2026 Guide
Tirzepatide is arguably the most significant advance in obesity pharmacology in a generation. Marketed as Mounjaro for type 2 diabetes and Zepbound for weight management, tirzepatide is the world's first approved dual GIP/GLP-1 receptor agonist—a novel mechanism that consistently outperforms everything that came before it. In
GLP-1
Tirzepatide (Mounjaro & Zepbound): The Complete 2026 Guide
Tirzepatide has quickly become one of the most talked-about medications in metabolic health — and for good reason. Whether you know it as Mounjaro (for type 2 diabetes) or Zepbound (for weight management), this dual-action molecule is rewriting what we thought was possible with pharmaceutical weight loss. Patients are losing 20%
GLP-1
Tirzepatide (Mounjaro & Zepbound): Complete Guide to Dosing, Weight Loss & Side Effects
Tirzepatide has quickly become one of the most talked-about medications in modern medicine — and for good reason. Marketed as Mounjaro for type 2 diabetes and Zepbound for chronic weight management, this weekly injection has produced weight loss results that surpass virtually every other pharmacological option available. But what exactly is
GLP-1
GLP-1 Drugs and Heart Health: What the Cardiovascular Trials Really Show
GLP-1
Tirzepatide vs. Semaglutide: The Definitive 2026 Head-to-Head Comparison
Two injectable medications are reshaping obesity medicine: tirzepatide (Mounjaro/Zepbound) and semaglutide (Ozempic/Wegovy). Both belong to the GLP-1 drug class, both are once-weekly injections, and both produce clinically meaningful weight loss. But the similarities mostly end there. In May 2025, the landmark SURMOUNT-5 trial published in the New England
GLP-1
Tirzepatide (Mounjaro/Zepbound): The Complete 2025–2026 Guide
GLP-1
Tirzepatide (Mounjaro & Zepbound): Complete Guide to Dosing, Benefits, and Side Effects
GLP-1
Tirzepatide (Mounjaro/Zepbound) Complete Guide: Dosing, Benefits, Side Effects & Comparison to Semaglutide (2026)
Tirzepatide — sold as Mounjaro for type 2 diabetes and Zepbound for weight loss — is one of the most significant advances in metabolic medicine in decades. As the first and only FDA-approved dual GIP/GLP-1 receptor agonist, it consistently outperforms older GLP-1 medications like semaglutide in head-to-head trials. This guide covers
GLP-1